Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,963 total articles
Netflix Chief Financial Officer Spencer Adam Neumann sold 28,630 shares of common stock at $98 per share on April 2, 2026, in a transaction reported on a Form 4 filed with the SEC. On the same day he exercised options to acquire an equal number of shares at strike prices of $36.408 and $38.105, with the option exercise totaling $1,055,546. After th…
BioAge Labs Chief Medical Officer Paul D. Rubin sold 8,820 shares on April 1, 2026, for $17.81 per share, generating $157,084, and on the same day exercised options to acquire 8,820 shares at strike prices of $4.11 and $6.57, valued at $44,572. The stock has risen roughly 415% over the past year and currently trades near $17.50, while InvestingPro …
Viant Technology Inc. Chief Financial Officer Larry Madden executed two stock sales on April 1 and April 2, 2026, disposing of 17,541 shares of Class A common stock for roughly $194,417 under a 10b5-1 trading plan adopted on December 15, 2025. The transactions follow a quarter in which Viant reported better-than-expected revenue, earnings, and adju…
Teladoc Health Chief Accounting Officer Joseph Ronald Catapano sold 675 shares on April 2, 2026, after exercising options to acquire 2,083 shares on April 1. The sale, disclosed on a Form 4, leaves Catapano with 10,249 shares. The transaction occurs amid analyst upgrades, activist calls for a $200 million buyback and a new board appointment.
Maurice Sciammas, Executive Vice President for Worldwide Sales & Marketing at Monolithic Power Systems Inc (MPWR), sold 30 shares on April 1, 2026, for $1,116.44 per share, yielding $33,493. The sale was made under a Rule 10b5-1 trading plan adopted on November 19, 2025. After the transaction, Sciammas directly holds 178,644 shares and also control…
Moody's Corp President and CEO Robert Fauber sold 875 shares of company stock on April 1, 2026, for $437.77 per share, generating $382,662 in proceeds. He also exercised options to acquire 1,167 shares, representing $163,409 in acquired value, and now directly holds 75488.918 shares. The transactions were carried out under a Rule 10b5-1 trading pla…
Regeneron Pharmaceuticals Inc. director Arthur F. Ryan sold 96 shares of the company on April 1, 2026, for $77,727 under a pre-established Rule 10b5-1(c) plan. The trades were carried out at prices between $771.32 and $779.71. After the sale, Ryan directly holds 17,603 shares. The stock was trading at $761.85, close to its 52-week high of $821.11, …
Avalo Therapeutics CFO Christopher Ryan Sullivan sold 16,059 shares across April 1 and 2, 2026, under a pre-established 10b5-1 trading plan, realizing $270,593 in proceeds. The trades occurred as Avalo shares have posted substantial gains over the past year and in the prior week, while several analysts reiterated or set Buy ratings and price target…
Senior Vice President Paul Cunningham sold 1,000 shares of Cadence Design Systems Inc on April 1, 2026, at $280.19 per share under a Rule 10b5-1 trading plan. The transaction reduced his holdings to 128,586 shares. The sale occurs amid mixed indicators for the stock - robust fiscal results and strategic moves on one hand, and valuation metrics and …
MGIC Investment CEO Timothy J. Mattke sold 139,202 shares on April 2, 2026, generating roughly $3.6 million in proceeds under a pre-arranged Rule 10b5-1 plan. The company reported fourth-quarter 2025 earnings with EPS matching analyst forecasts at $0.75 but revenue of $298.65 million, falling $9.54 million short of expectations. Despite the sale, m…
Avalo Therapeutics' Chief Medical Officer, Doyle Mittie, completed a matched exercise-and-sale transaction on April 1, 2026, selling 679 shares of common stock at $16.00 and exercising options to buy 679 shares at $8.04. The moves were conducted under a pre-arranged Rule 10b5-1 plan adopted November 13, 2025. Meanwhile, several analysts reiterated …
Samsara Inc.'s Chief Financial Officer Dominic Phillips sold 20,139 Class A shares on April 1, 2026, for $640,673 under a pre-arranged Rule 10b5-1 plan. The transaction leaves Phillips with significant direct and indirect holdings while analysts balance the company’s robust quarterly ARR growth and customer gains against valuation considerations.
Regan Mills, President of Product Test at Teradyne (NASDAQ: TER), sold 252 shares on April 2, 2026, for $73,301 and had 222 shares withheld on April 1, 2026, to cover taxes tied to RSU vesting. The transactions were conducted under a Rule 10b5-1 trading plan. Teradyne recently unveiled two automated test platforms and drew analyst target increases …
GlobalFoundries Chief Business Officer Michael James Hogan sold 1,800 ordinary shares on April 1, 2026, for $81,072 and gave 150 shares as a gift the same day. The transactions were completed under a pre-existing Rule 10b5-1 trading plan and are permitted by a lock-up agreement tied to an offering by the issuer's majority shareholder. Separately, G…
Forager Fund, L.P. and related parties sold 950,000 shares of Repay Holdings Corp (NASDAQ: RPAY) Class A common stock across two transactions on April 1 and 2, 2026, realizing $2,408,383 in proceeds. The dispositions left Forager Fund with a direct stake of 10,192,937 shares. The activity coincides with Repay reporting a Q4 2025 earnings beat, anno…
Sheela Kosaraju, Senior Vice President and General Counsel at Ciena (NASDAQ: CIEN), sold 2,012 shares of company common stock on April 1, 2026, for $401.71 per share, generating proceeds of $808,240. The transaction was carried out under a Rule 10b5-1 trading plan established October 14, 2025. Ciena recently reported a strong fiscal first quarter a…
John McCartney, a director at Huron Consulting Group Inc., sold 500 shares on April 1, 2026, under a Rule 10b5-1 plan for $63,840. The transaction occurred as the stock traded at $130.35, down about 25% year-to-date. Huron reported fourth-quarter adjusted EPS above expectations and revenue growth, yet shares declined after management provided a wid…
Ceribell Chief Technology Officer Raymond Woo executed a sale of 11,112 shares of common stock on April 1, 2026, for roughly $206,243 at prices near the prevailing market. The transaction coincided with option exercises and issuance of restricted stock units, and comes as the company announced an FDA Breakthrough Device Designation for its Large Ve…
Thomas E. Chorman, a director at Standex International Corp (NASDAQ:SXI), sold 50 shares on April 1, 2026, under a 10b5-1 trading plan for $257.94 per share, a transaction valued at $12897. The sale was disclosed on a Form 4 filing with the SEC. The company recently reported second-quarter fiscal 2026 results that exceeded consensus on both earning…
Ciena Corp's President and CEO, Gary B Smith, disposed of 2,952 shares on April 1, 2026, in a transaction totaling $1.23 million, according to a Form 4 filing. The sale was made under a Rule 10b5-1 trading plan established on October 4, 2025. The move comes amid elevated share prices, sizable year-over-year gains, multiple analyst price-target incr…
TaskUs Chief Customer Officer Jarrod Johnson sold 36,406 shares of Class A common stock in two transactions on April 1 and 2, 2026, netting $248,113. The insider sales occurred while TaskUs shares traded near their 52-week low and after the company disclosed strong fourth-quarter 2025 results and a $600 million refinancing package that funded a spe…
Ilene Eskenazi, a director at A.K.A. Brands Holding Corp (NYSE: AKA), sold 12,201 shares on November 12, 2025, for about $157,270. The sale occurred at prices between $12.28 and $13.655, with a volume-weighted average price of $12.89. After the transaction Eskenazi directly holds 5,852 shares. The sale comes as AKA shares trade at $10.49 and as the…
Neuraxis Chief Financial Officer Timothy Robert Henrichs acquired 7,593 shares of the company's common stock on April 1, 2026, paying $1.96 per share for a total of $14,882, according to a Form 4 filing. The purchase occurred while the stock trades substantially higher than the acquisition price and after the company reported revenue growth alongsi…
Thomas Joeseph Carrico, who holds multiple executive titles at Neuraxis, INC (NASDAQ: NRXS), purchased 667 shares at $1.96 on April 1, 2026, totaling $1,307. The stock has since risen to $7.25, producing a large unrealized gain relative to the purchase price. Neuraxis reported a 27% year-over-year revenue increase to $968,000 in Q4 2025 but widened…
Neuraxis, INC Chief Executive Officer Brian Allen Carrico acquired 8,060 shares of the company’s common stock on April 1, 2026, at $1.96 per share for a total of $15,797. Following the trade he directly holds 348,178 shares. Since that purchase, the stock has climbed to $7.25, a near 270% increase from his buy price, and the company's market capita…
